The abdomen typically has more subcutaneous fat and is the most common injection site, where 4 mm needles are generally sufficient
Burmeister MA, Ayala JE, Smouse H, Landivar-Rocha A, Brown JD, Drucker DJ, et al
See how science, strategy, and innovation are transforming the GLP-1 space: #GLP1 #oralGLP1 #metabolichealth #diabetescare #obesity #obesitytreatment #pharmainnovation #futureproofingbusinesses #IeB To view or add a comment, sign in #MIMSPharmaMarketInsightUpdate, September 2025 Including: SGLT2 inhibitors should be offered first-line to people with heart failure with reduced ejection fraction A new formulation of Rybelsus (semaglutide) tablets has been released The first inhaled levodopa product, Inbrija (levodopa), has been launched
Mistake 2: Not eating enough protein